Quotes

1. The progression to 1 um extreme resolution imaging is an exciting advancement for our Envisu R-Class research product line...The importance of this innovation is that it offers researchers true cellular-level in vivo optical histology. This Extreme High Resolution (XHR) capability is unlocked only by the combination of Bioptigen’s patented spectrometer and signal processing technologies with the NKT Photonics SuperK supercontinuum source.

   In Bioptigen introduces 1 µm resolution SD-OCT imaging system in collaboration with NKT Photonics supercontinuum white light laser source at ARVO conference in Seattle

2. The progression to 1 µm extreme resolution imaging is an exciting advancement for our Envisu R-Class research product line

   In Bioptigen introduces 1 µm resolution SD-OCT imaging system in collaboration with NKT Photonics supercontinuum white light laser source at ARVO conference in Seattle

3. This year has been positively monumental for Bioptigen. “Now that we’ve been cleared to market Envisu practically worldwide, we’re seeing increased demand from clinicians and researchers who appreciate the convenience and flexibility our hand-held scanner provides for patients who can’t be imaged using traditional, tabletop devices.

   In Bioptigen Expands Headquarters Within Research Triangle Park, NC

4. Our devices are generally indicated for patients who are not well suited to imaging with traditional, tabletop devices...Bioptigen’s Envisu ophthalmic imaging devices provide a unique degree of flexibility that benefits clinicians and the patients they care for. It’s exciting to be able to market our C-series devices in the United States and support efforts by health-care providers to deliver appropriate medical interventions, especially for the underserved pediatric patient population.

   In Bioptigen Receives FDA Clearance to Market Envisu Imaging Systems in the USA

5. Now that Bioptigen has regulatory approval to market our technology in Canada and the European Union, adults and children can begin benefitting from this flexible and detailed imaging platform that complements existing diagnostic techniques and treatments.

   In Bioptigen Receives Clearance to Market Envisu SDOIS in Canada

6. "It can't just be about billion-dollar wins that VCs target...We need investments in small and medium-size companies that feed the ecosystem....It's really horrible...I think Congress has no idea of their impact on small business...My neighbor is a staunch Republican...we both agree that if you can get reasonable people to sit down together, they can reach an agreement...This polarization is killing us...We've got to get through that, if we're going to get through this malaise.

   In This Is What Job Creation Really Looks Like

7. Our hand-held technology allowed surgeons to bring the imager to the elephant, which obviously is better than having to bring an elephant to an imager,” Buckland said. “And the attributes of our Envisu system allowed users to modify it for the unique size of an elephant’s eye. No other product on the market can do that.

   In Bioptigen Envisu SDOCT Used in Rare Elephant Cataract Surgery

8. Our hand-held technology allowed surgeons to bring the imager to the elephant, which obviously is better than having to bring an elephant to an imager.

   In Bioptigen Envisu SDOCT Used in Rare Elephant Cataract Surgery

9. Physicians in Europe play a critical role when it comes to advancing non-invasive medical technologies...Bioptigen looks forward to collaborating with these professionals as they develop new best practices based on standards that benefit patients worldwide.

   In Bioptigen's Ophthalmic Imaging System Receives CE Mark

10. Earning a CE Mark is an important milestone for Bioptigen, but it's even more meaningful for the pediatric and adult patients who now can benefit from our more flexible imaging platform. We bring imaging to the patient; the patient doesn't have to come to us.

    In Bioptigen's Ophthalmic Imaging System Receives CE Mark